fra Rainman da rekner eg med?
3 Likes
åja trudde det var dette:)neida!!!
2 Likes
TI = Cuba Gooding jr.
Var ikke dette tilfellet også før forrige emisjon?
1 Like
Myrlid er vel heilt ute av Targovax, kunne jo kjøpt for litt av pengene han fikk for Pcib aksjene han solgte no🙂På hvilken kurs solgte Myrlid seg ut av Targo?
2 Likes
Joda. Hørt det før. Best in class, men nå forbikjørt. Så for all del.
2 Likes
Vi skulle hatt inn en person med salgsferdighetene til Elizabeth Holmes. Her her det jo muligheter for å selge noe med substans i tillegg.
Det er penger der ute, så det er bare et spørsmål om verdiene som vi har sponset frem blir ivaretatt. Det er jo en av oppgavene til styret? De som jobber for aksjonærene.
1 Like
Dersom rett RA så mener jo selskapet og andre at det er mere å hente fra Oncos ! derav studiet sammen med aGenus som (håper jeg) kan øke PR/CR til noe større enn Merc’s Keytruda klarer i dag og endog være i front i resultater av konkurrenter da vi nå kjører med 2 gen CPI … ““there is hope in hanging snår”” - he-he !
5 Likes
Ligger kanskje et par år på etterskudd pga manglende finansiering underveis, og kommer dermed på etterskudd i forhold til konkurrenter ?
1 Like
4 Likes
Veldig bra for Targovax sine studier:+1:
1 Like
Forklar oss hobbyinvestorane kvifor?
Medisinen her er den som Targovax skal kombinere med sitt virus i melanomstudiet. At Botensilimab er potent vil påvirke resultatene. Samtidig er det et godt rasjonale for kombinasjonen med denne typen sjekkpunkthemmer basert på de undersøkelsene og funnene Targovax har gjort ifbm sitt pilotstudie.
Så, Botensilimab funker bra og Oncos har potensiale til å fungere bedre sammen med denne enn feks Keytruda. Her skal vi i kommende studie sammenligne og ha fokus på hva som bidrar og om vi får en, forhåpentligvis 1+1 = >2 effekt.
Samtidig har Agenus et studie som heter ACTIVATE, hvor de kjører kun Botensilimab på samme type pasienter. Her har Targovax tilgang til data. Dette vil kanskje muliggjøre samkjøring av registreringsstudie, for de som er heldige å ta det. Det blir ikke Targovax. Vi skal bare gjøre oss uimotståelige for noen andre å ta den biten.
Overførbarhetspotensialet til andre krefttyper med samme profil er absolutt tilstede.
Jeg tenker timingen er bra, og at vi ikke nødvendigvis er forbikjørt av andre, for denne kombinasjonen har potensiale til å bli langt bedre. Det er hvertfall mulig fra et biologisk perspektiv.
12 Likes
takk Takk🙂
Mer om Agenus+botensilimmab+balstilimab og studien/data på ASCO-GI 2023
A combination of two next-generation immunotherapy drugs has shown promising clinical activity in treating patients with refractory metastatic colorectal cancer, a disease which has not previously responded well to immunotherapies, according to a Dana-Farber Cancer Institute researcher.
The results of an expanded phase 1 trial of the two drugs, botensilimab (CTLA-4 inhibitor) and balstilimab (PD-1 inhibitor), are to be presented at the ASCO Gastrointestinal Cancers Symposium Jan. 19-21 in San Francisco. The study is led by Benjamin L. Schlechter, MD, a senior physician in the Gastrointestinal Cancer Treatment Center at Dana-Farber.
The trial included 70 patients with metastatic colorectal cancer who had been previously treated with several lines of drugs, including immunotherapies. These patients all had tumors termed microsatellite stable, or MSS, meaning that their genes for repairing certain types of DNA damage were intact. MSS colorectal tumors account for the vast majority of colorectal cancers, and the first generation of immunotherapy drugs have had little effect on them. While immunotherapy has succeeded in microsatellite unstable (MSI) colorectal cancers, only about 3-5% advanced colorectal cancers are MSI and there are no approved immunotherapies for the far more common MSS colorectal cancers.
The two-drug combination being tested in the expanded phase 1a/1b trial of patients with metastatic MSS colorectal cancers were novel, next-generation antibodies. Botensilimab is an antibody directed against the T-cell receptor cytotoxic T-lymphocyte-associated antigen 4, or CTLA-4, which is an immune checkpoint that regulates T-cell activation. Balstilimab is a novel monoclonal antibody designed to block PD-1 – another immune checkpoint protein – from interacting with PD-L1 and PD-L2. By inhibiting this interaction, balstilimab is aimed at freeing the immune system to attack cancers.
The patients in the trial were followed for a median of 7 months after receiving the drug combination. During that period, 23% of the patients had a reduction in the size of their tumors, and the median duration of response was not reached. The disease control rate – the percentage of patients with metastatic cancer who had a complete or partial response and stable disease – was 76%. The 12-month overall survival was 63%. The main population of patients who benefited from the combination were those who did not have active metastatic cancer in their liver.
Treatment-related adverse events occurred in 91% of patients, including grade 3 in 40% and grade 4 in 3%. Twelve percent of patients discontinued both drugs because of adverse events.
The researchers concluded that “in patients with heavily pretreated metastatic MSS colorectal cancer, botensilimab plus balstilimab continues to demonstrate promising clinical activity with durable response, and was well tolerated, with no new immune-mediated safety signals.”
“Harnessing the power of immune therapy in refractory colorectal cancer has been a key goal of multiple clinical trials in advanced colorectal cancer, but in MSS colorectal cancer efforts have been universally disappointing,” said Schlechter. “These data are a meaningful and important advance in the care of this very sick population.”
Based on these findings, a randomized phase 2 trial in patients with MSS colorectal cancer is currently enrolling.
Funding for this research comes from Agenus, Inc.
9 Likes
“Rapidly create value” sier Targovax. Hva sier "ekspertene?
“I think cancer vaccines will be an important part of cancer therapies in the future"
(Greenberg - AACR President-Elect Philip D. Greenberg, MD, FAACR, editor-in-chief of the AACR journal Cancer Immunology Research , professor and head of the Program in Immunology, Clinical Research Division, and the Rona Jaffe Foundation Endowed Chair at the Fred Hutchinson Cancer Center)
5 Likes
Vi får forkorte ventetiden på gode nyheter med å følge på med det vi vet skjer. Tirsdag 24 januar i Boston. CRNA Hansen og Levinsky skal representere Targovax.
EDW har nok ikke tid da han og Gaal må arbeide med avtaler og finansene😀
Welcome to the RNA CTx Summit
While CTx is rapidly becoming the 3rd pillar of medicine, and RNA engineering promises improved safety, functionality and scalability profiles to accelerate to approval. Now is the time to gather this burgeoning community together to overcome the specific challenges associated with RNA CTx development to accelerate these promising therapies through the value chain.
Experts will unite over three days, including two deep-dive workshops , dedicated Q&As , interactive panel discussions and highly appraised networking opportunities to meet and learn from the pioneers taking this field forward.
Tackle the top 5 priorities in the field, including:
Progress cell-specific RNA delivery methods for efficient CTx transfection and prevent off-target toxicity with BioNTech , Gamida Cell and Targovax
9 Likes
Kommentaren til Birgitte kan understøttes ved EW sitt utsagn på høstens pizzakveld.
-
EW og Gaal brukte allerede da 100% av sin tid på det finansielle.
-
Fikk åpne dører der hvor de ikke hadde hatt tilgang eller avvist tidligere.
-
Utelukkende internasjonalt fokus. Vanskelig (les håpløst) å finne noen med kompetanse til å vurdere verdien og R/R i Norge.
13 Likes
Det har sikkert vært delt her tidligere, men prøvde å søke på navnet hennes her inne uten å finne noe:
12 Likes